<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02980458</url>
  </required_header>
  <id_info>
    <org_study_id>1221def09ct</org_study_id>
    <nct_id>NCT02980458</nct_id>
  </id_info>
  <brief_title>Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration</brief_title>
  <official_title>Characterisation of Relative Bioavailability of a Generic Deferiprone Formulation in Comparison With a Marketed Reference Product in a Single Dose, 2-period-crossover Design Under Fasting Conditions; Controlled, Open, Randomised, no Blinded Study With Bioequivalence Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SocraTec R&amp;D GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SocraMetrics GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SocraTec R&amp;D GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will be conducted in order to compare the bioavailability of the generic&#xD;
      Test product (Deferiprone 500 Lipomed tablets, Lipomed AG, Switzerland) with a marketed&#xD;
      Reference product (Ferriprox® film-coated tablets, Apotex Europe B.V., Germany) both&#xD;
      containing 500 mg deferiprone. For this issue the pharmacokinetics will be characterised&#xD;
      after single dose administration of each one tablet.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed in an open-label, randomised (order of treatments), single dose,&#xD;
      2 period cross-over design with a wash out phase of at least three treatment free days&#xD;
      between both administrations. Sample collection will be performed over eight hours after&#xD;
      fasted administration. This time is considered adequate for the determination of plasma&#xD;
      concentration vs. time profiles long enough for reliable estimation of the extent of&#xD;
      absorption, i.e. the AUC derived from measurements is expected to cover at least 80% of the&#xD;
      AUC extrapolated to infinity for deferiprone&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-tlast) for deferiprone</measure>
    <time_frame>8 hours interval</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) for deferiprone</measure>
    <time_frame>8 hours interval</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>from fist dose until discharge of the subject (approx. 2 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Deferiprone 500 Lipomed film-coated tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral fasted administration of one film-coated tablet of Deferiprone 500 Lipomed film-coated tablets (Lipomed AG, Switzerland), containing 500 mg deferiprone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferriprox® film-coated tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral fasted administration of one film-coated tablet of Ferriprox® film-coated tablets (Apotex Europe B.V., Germany), containing 500 mg deferiprone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone 500Mg Tablet</intervention_name>
    <arm_group_label>Deferiprone 500 Lipomed film-coated tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone 500 MG Oral Tablet [Ferriprox]</intervention_name>
    <arm_group_label>Ferriprox® film-coated tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. sex: male&#xD;
&#xD;
          2. ethnic origin: Caucasian&#xD;
&#xD;
          3. age: 18 years or older&#xD;
&#xD;
          4. body-mass index (BMI): &gt;=18.5 kg/m² and &lt;= 30.0 kg/m²&#xD;
&#xD;
          5. good state of health&#xD;
&#xD;
          6. non-smoker or ex-smoker for at least 1 month&#xD;
&#xD;
          7. written informed consent, after having been informed about benefits and potential&#xD;
             risks of the clinical trial, as well as details of the insurance taken out to cover&#xD;
             the subjects participating in the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. existing cardiac and/or haematological diseases or pathological findings, which might&#xD;
             interfere with the safety or tolerability of the active ingredient&#xD;
&#xD;
          2. existing hepatic and/or renal diseases or pathological findings, which might interfere&#xD;
             with the safety or tolerability, and/or pharmacokinetics of the active ingredient&#xD;
&#xD;
          3. existing gastrointestinal diseases or pathological findings, which might interfere&#xD;
             with the safety, tolerability, absorption and/or pharmacokinetics of the active&#xD;
             ingredient&#xD;
&#xD;
          4. history of relevant CNS and/or psychiatric disorders and/or currently treated CNS&#xD;
             and/or psychiatric disorders&#xD;
&#xD;
          5. known allergic reactions to the active ingredients used or to constituents of the&#xD;
             pharmaceutical preparations&#xD;
&#xD;
          6. subjects with severe allergies or multiple drug allergies unless it is judged as not&#xD;
             relevant for the clinical trial by the investigator&#xD;
&#xD;
          7. heart rate &lt; 50 bpm&#xD;
&#xD;
          8. laboratory values out of normal range unless the deviation from normal is judged as&#xD;
             not relevant for the clinical trial by the investigator&#xD;
&#xD;
          9. laboratory values: CRP &gt; 5 mg/L, ASAT &gt; 20 % ULN, ALAT &gt; 10 % ULN, bilirubin &gt; 20 %&#xD;
             ULN and creatinine &gt; 0.1 mg/dL&#xD;
&#xD;
         10. positive anti-HIV-test (if positive to be verified by western blot), HBs-AG-test (if&#xD;
             positive to be verified by test for HBc-IgM) or anti-HCV-test&#xD;
&#xD;
         11. history of recurrent episodes of neutropenia or history of agranulocytosis&#xD;
&#xD;
         12. acute or chronic diseases which may interfere with the pharmacokinetics of the IMP&#xD;
&#xD;
         13. history of or current drug or alcohol dependence&#xD;
&#xD;
         14. regular intake of alcoholic food or beverages of ≥ 40 g pure ethanol for male per day&#xD;
&#xD;
         15. subjects who are on a diet which could affect the pharmacokinetics of the active&#xD;
             ingredient&#xD;
&#xD;
         16. regular intake of caffeine containing food or beverages of ≥ 500 mg caffeine per day&#xD;
&#xD;
         17. blood donation or other blood loss of more than 400 ml within the last 2 months prior&#xD;
             to individual enrolment of the subject&#xD;
&#xD;
         18. administration of any investigational medicinal product during the last 2 months prior&#xD;
             to individual enrolment of the subject&#xD;
&#xD;
         19. regular treatment with any systemically available medication&#xD;
&#xD;
         20. treatment with medicinal products which might cause neutropenia or agranulocytosis&#xD;
&#xD;
         21. subjects, who report a frequent occurrence of migraine attacks&#xD;
&#xD;
         22. subjects suspected or known not to follow instructions&#xD;
&#xD;
         23. subjects who are unable to understand the written and verbal instructions, in&#xD;
             particular regarding the risks and inconveniences they will be exposed to during their&#xD;
             participation in the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelius Koch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SocraTec R&amp;D GmbH, Clinical Pharmacology Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SocraTec R&amp;D GmbH Clinical Pharmacology Unit</name>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Deferiprone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

